News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Lancet Neurology Study: Promising Lou Gehrig’s Disease Drug Fails Trial
November 1, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON (Reuters) - An acne drug that had shown early promise in treating the degenerative nerve condition known as Lou Gehrig's disease actually worsens it, a study in Lancet Neurology said on Thursday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Europe
MORE ON THIS TOPIC
IN PARTNERSHIP WITH TAKEDA
Takeda’s Commitment to Trial Representation is Shaping the Future of Clinical Research
January 5, 2026
·
5 min read
·
BioSpace Insights
Depression
Biohaven Notches Another Psychiatric Failure Months After Key FDA Rejection
January 2, 2026
·
1 min read
·
Annalee Armstrong
Phase III
Ultragenyx Loses $1B in Market Value as Bone Drug Fails To Reduce Fractures
January 2, 2026
·
2 min read
·
Annalee Armstrong
Alzheimer’s disease
In Novo’s GLP-1 Failure, Alzheimer’s Space Spies a Combination Opportunity
January 2, 2026
·
5 min read
·
Annalee Armstrong
